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Abstract 
Abstract: Hot melt extrusion has been used to produce a solid dispersion of the 
thermolabile drug artemisinin. Formulation and process conditions were optimised 
prior to evaluation of dissolution and biopharmaceutical performance. Soluplus®, a 
low Tg amphiphilic polymer especially designed for solid dispersions enabled melt 
extrusion at 110ºC although some drug-polymer incompatibility was observed. 
Addition of 5% citric acid as a pH modifier was found to suppress the degradation. 
The area under plasma concentration time curve (AUC0-24hr) and peak plasma 
concentration (Cmax) were four times higher for the modified solid dispersion 
compared to that of pure artemisinin.  
Key words: Extrusion, thermolabile drug, artemisinin, Soluplus®, compatibility, 
bioavailability.  
1. Introduction  
Hot melt extrusion (HME) has been widely used in the pharmaceutical industry to 
prepare solid dispersions to improve bioavailability of poorly water soluble drugs1,2. 
During processing of solid dispersions by HME, the hydrophobic drug is processed with 
a thermoplastic polymer in the molten state to obtain a stabilised amorphous form. In 
HME the selection of a suitable polymer plays a vital role in successful formulation, in 
addition to the choice of suitable extrusion conditions. Typically the extrusion process 
should be carried out at least 20-40° C above the glass transition temperature (Tg) of the 
polymer. The suitability of a polymer for HME can be determined by its thermal and 
rheological properties3.  
Exposure of material to high temperature is one of the major concerns during HME, as 
this may adversely affect stability of the drug4 or polymer5. There are also increased 
chances of interaction between drug and polymer at high temperature and shear during 
HME. This degradation or interaction may result in generation of impurities5,6, 
unexpected change in rheology of the melt7 or discolouration of the product5. 
Processing at high temperature is not suitable for some Active Pharmaceutical 
Ingredients (APIs) due to thermal decomposition which may be followed by loss of 
pharmacological activity8 and therefore prevention of degradation is a major challenge 
during extrusion processing. These issues have restricted pharmaceutical applications of 
HME, yet to date relatively few reports are available on these degradation issues. In 
such cases, the addition of plasticizer is one of the approaches used to lower the Tg and 
melt viscosity, allowing extrusion to be performed at lower temperatures9,10. Lowering 
the processing temperature can reduce degradation of the drug and facilitate drug 
stability in pharmaceutical formulations11 however, the added plasticiser contributes 
significantly to the bulk of the formulation and can adversely affect the mechanical 
properties, drug release rate and stability of the final product12. Therefore, alternative 
approaches are required to facilitate the processing of thermally sensitive drugs. The 
objective of this work is to investigate and address challenges in the application of 
HME for processing solid dispersions containing the thermolabile drug, artemisinin 
using a recently introduced low Tg polymer.  
Artemisinin, a keystone of malaria treatment, is effective against Plasmodium 
falciparum infection and cerebral malaria13. Artemisinin has low bioavailability and 
poor water solubility; its molecular structure is displayed in Fig. 1. Due to its 
thermolabile nature, artemisinin poses significant processing challenges to forming 
solid dispersions14. Several studies have described attempts to improve the solubility of 
artemisinin, such as micronisation using supercritical fluid technology, solid dispersions 
prepared using a solvent evaporation method15 and complexation16,17.  However, these 
methods are complex, difficult to scale-up and yielded relatively poor improvements in 
drug release properties. Here, an amphiphilic graft copolymer, Soluplus® (polyvinyl 
caprolactum polyvinyl acetate polyethylene glycol) was used to form solid dispersions 
with artemisinin using HME, as it has the ability to enhance the solubility of poorly 
water soluble drugs and is suitable for melt extrusion below 120°C, without the need for 
incorporation of additional plasticiser18,19.  
During preformulation the polymeric matrix is selected on the basis of drug-polymer 
miscibility, glass transition temperature and rheology of the mixture in the molten state. 
Screening at the preformulation level generally involves thermal analysis, rheological 
testing, miscibility predictions using the Florey–Huggins equation and hot stage 
microscopy20,21. Oscillatory rheometry can also be used to study flow behaviour and 
stability of the drug polymer mixture under oscillatory shear. This enables the structural 
dynamics of complex fluids to be investigated at precisely controlled temperature and 
deformation. Here, oscillatory rheometry has been used as a screening tool to optimise 
processing temperatures and drug loading and to study the effect of additives under 
shear. Particular challenges included processing, stability and biopharmaceutical 
performance, all of which are described in detail.          
2. Materials and methods  
Artemisinin was supplied from Cipla Pharmaceuticals Ltd (ART25062007). Soluplus® 
was kindly provided by BASF Chemicals. All other chemicals and solvents used were 
of analytical grade.  
2.1. Thermal analysis 
The onset of thermal degradation of artemisinin and Soluplus® was analysed using a 
Q5000 Thermo Gravimetric Analyser (TGA) (TA Instruments, UK) equipped with a 
RSC90 cooling unit. Each aluminium pan was calibrated for mass before loading. 
Approximately 5 mg of sample was loaded into each aluminium pan and heated at a rate 
of 10°C/min over the temperature range 25 to 200°C. An inert atmosphere was 
maintained by purging with nitrogen gas at a flow rate of 30 ml/min. Differential 
Scanning Calorimetry (DSC) studies were carried out using a Q2000 DSC (TA 
Instruments, UK) equipped with an RSC90 cooling unit. Indium standards were used to 
calibrate the DSC temperature and enthalpy scales. For each test approximately 4 mg of 
sample was hermetically sealed in an aluminium pan and a similar empty pan used as a 
reference. The pans were heated at a constant rate of 10○C/min over a temperature range 
of 25 to 170○C for artemisinin and from 25 to 200○C for Soluplus®. An inert 
atmosphere was maintained by purging nitrogen at a flow rate of 50 ml/min.    
2.2. Oscillatory Rheometry 
The rheological behaviour of artemisinin, Soluplus® and physical mixtures in different 
ratios was studied using an MCR 501 rotational rheometer (Anton Paar, Austria), 
equipped with a temperature controlled chamber. Physical mixtures of artemisinin and 
Soluplus® were prepared in 1:1, 1:3 and 1:5 ratios (w/w) (50, 25 and 16.7% (w/w) 
respectively) by blending in a Turbula mixer for 10 minutes. Parallel plates of diameter 
25 mm were used for rheological characterisation with the distance between the plates 
set to 1 mm. The polymer or physical mixture was added to the bottom plate and 
preheated to the set temperature for 5 minutes. The separation distance between the 
plates was then reduced to 1 mm. Time-dependent stability of melts was measured by 
maintaining a constant oscillation frequency and strain over a fixed period of time. This 
test was performed at temperatures of 100, 110 and 130°C, at a strain of 1% and a 
frequency of 10 Hz for 30 minutes, whilst complex viscosity was measured every 5 
seconds.  
2.3. Extrusion of artemisinin and Soluplus® 
Extrusion was carried out using a co-rotating twin screw extruder (Pharmalab, Thermo 
Scientific, UK) with a screw root diameter of 16 mm and a maximum screw length to 
diameter ratio of 40:1. Two extruder temperature profiles were applied (T110A and 
T110B as detailed in Table 1) at a constant screw rotation speed of 50 rpm. Residence 
time (i.e. the amount of time the extruded material spends at temperature inside the 
process) has a significant impact on the quality of the extruded material. Here two 
different screw lengths were employed to study the effect of residence time; the longer 
extruder screws corresponding to higher residence time. Half and full screw lengths 
were employed, as described in Table 2. Powdered blends of artemisinin and polymer 
were fed into the extruder at a rate of 120 g/h using a gravimetric twin screw feeder 
(Brabender, Germany). Each batch was of 50g. Extruded formulations were labelled 
ArtSD1, ArtSD2 and ArtSD3 (detailed formulation codes with processing parameters 
are provided in Table 3). Following extrusion, the extruded strand was air cooled and 
pelletized. The pellets were of 2mm diameter and 1mm thickness. Extrudates were 
subsequently milled and analysed through powder X-ray diffraction (PXRD), DSC, in-
vitro dissolution and pharmacokinetic studies.   
2.4. Powder X-ray diffraction 
PXRD patterns were recorded using an X-ray Bruker D8 powder diffractometer with an 
X-ray wavelength of 0.154 nm, Cu source, 40 keV voltage and a filament emission of 
40 mA. Samples were scanned from 2 to 30° (2θ) using a 0.01° step width and a 1 
second time count. The scatter slit was set at 0.2○ and the receiving slit at 1○. 
2.5. Assay 
Solid dispersions equivalent to 20 mg of artemisinin were weighed accurately and 
dissolved in a suitable quantity of medium containing 10% (v/v) ethanolic water and 
0.1% (w/v) sodium lauryl sulphate. An appropriate quantity was alkali treated using 
0.2% NaOH. Drug content was measured at 290 nm using a UV spectrophotometer. 
Analysis of data was performed using PCP-Disso software (Poona College of 
Pharmacy, V3, Pune, India). 
2.6. In-vitro Dissolution 
In-vitro dissolution studies were performed using a USP-XXVI type 2 paddle test 
apparatus (Copley Scientific, UK). Pellet samples equivalent to 20 mg of artemisinin 
were placed in dissolution vessels containing 600 ml of dissolution medium maintained 
at 37○C +0.1○C and stirred at 100 rpm. The dissolution medium consisted of ethanol 
10% ethanolic water and sodium lauryl sulphate (0.1% w/v).  Samples were collected 
periodically and replaced with fresh dissolution medium. The collected sample was 
filtered using a 0.45µm cellulose acetate filter and treated with alkali. The concentration 
of artemisinin was determined spectrophotometrically at 290 nm. Data was analysed by 
PCP Disso software V3 (Poona College of Pharmacy, Pune, India). 
2.7. Pharmacokinetic study 
Study protocol 
A study was performed with prior approval from the Institutional Animal Ethical 
Committee (IAEC) of C U Shah College of Pharmacy, Mumbai, India whose guidelines 
were followed throughout the studies. 36 healthy albino wistar rats with a weight 180-
200 gm were divided into three groups; control, pure drug and ArtSD3. A sparse 
technique was used to collect blood samples (n = 6). The animals were housed in 
standard metabolism cages and fasted for 12 hours before dosing but allowed free 
movement and access to water throughout the experiment. 100 mg of artemisinin was 
dispersed in 0.5% aqueous carboxymethyl cellulose (CMC) solution and the oral dose 
(equivalent to 100 mg of artemisinin) was administered using an oral syringe. At 
predetermined time intervals, blood samples were obtained by the retro orbital 
technique and collected in ethylene diamine tetra acetic acid (EDTA) tubes. 
Sample analysis 
Plasma was obtained by centrifugation of the blood sample at 3500 rpm for 15 minutes. 
A volume of 200 µl plasma was pipetted into Eppendorf tubes and 100 µl of internal 
standard (artemether solution 1000 µl/ml) and 700 µl methanol were added. The 
solution was vortexed for 2 minutes and the organic phase separated by centrifugation. 
The collected sample was then subjected to analysis by HPLC (Agilent Technologies, 
1200 series, Wokingham, UK). The plasma level of artemisinin was analysed by HPLC 
using 65% acetonitrile and 35% water as the mobile phase. The HPLC system utilised a 
UV detector set at 210 nm and a C18 column (250 x 4.6 mm). Artemisinin exhibits a 
maximum UV absorption at 210 nm. The limits of detection and quantification were 
1.01 and 3.06 µg/ml, respectively. The concentration against peak area graph plot was 
found to be linear (r2 = 0.998).  
2.8. Stability 
All extrudates were stored at room temperature in a desiccator at 33% RH and their 
stability was studied at 1 month, 3 months, 6 months, 9 months and 12 months by 
PXRD and dissolution using the above method. The PXRD patterns of ArtSD3 at 1 
month, 3 months, 6 months, 9 months, 12 months and 24 months are shown in figure 10. 
There was no variation in the result due to time, which proves that the stability of the HME 
prepared artemisinin: Soluplus® solid dispersions. 
3. Results and Discussion  
Prior to extrusion, all API-polymer mixtures were studied using thermal and rheological 
analysis. These results are described initially, prior to extrusion results and 
characterisation of the extruded formulations being presented. 
Thermal analysis 
HME is performed at an elevated temperature and therefore it is necessary to determine 
the onset of degradation of the API and polymer. Thermo-gravimetric analysis (TGA) 
was carried out to determine the onset of degradation of pure artemisinin and Soluplus® 
(Fig. 2). Results showed the onset of degradation of pure artemisinin at 160°C and rapid 
weight loss from 170°C. This degradation was found to result in a mass loss of 15.73% 
between 170°C and 200°C whereas Soluplus® demonstrated good thermal stability up 
to 200°C. Soluplus® showed the presence of moisture at a level of 2-5% (w/w), 
evidenced by a mass loss up to a temperature of 100°C. 
Rheological Characterisation  
API and polymer interaction was evaluated using oscillatory rheometry. Samples may 
undergo structural changes such as plasticisation, cross linking and change in scissor or 
degradation when subjected to high temperature and shear for extended periods of time; 
time dependent data obtained by oscillatory rheometry can be similar to typical HME 
residence times. Ideally, the viscosity of the polymer should remain constant at a given 
temperature; changes in viscosity may indicate structural changes in the material. From 
the TGA results discussed above, temperatures of 110 and 130°C were selected for 
rheological characterisation. The complex viscosities of the polymer with different drug 
loadings subjected to constant oscillatory shear at 110°C and 130°C are shown in Fig.3. 
For pure Soluplus®, the viscosity remained stable for 20 minutes at 110°C and 130°C. 
The plasticising effect of artemisinin can be clearly observed as a reduction in complex 
viscosity with increasing drug loading; a colour change of the material from white to 
brown was also observed, suggesting that degradation had occurred during the test. No 
discolouration was observed when Soluplus® and artemisinin were separately subjected 
to oscillatory rheometry at the highest set temperature of 130°C, indicating an 
interaction between the two materials lead to the observed degradation. Colour changes 
in samples tested at 110°C were less intense than samples processed at 130°C and the 
level of applied shear did not significantly affect the colour or colour intensity of the 
samples. The colour change was found to occur after approximately 10 minutes of shear 
application, indicating a time and temperature dependent interaction.    
It is reported that although artemisinin itself is acidic in nature, it contains a 
sesquiterpene lactone ring with an unusual peroxide bridge22. This lactone ring 
undergoes electrochemical reduction at a basic pH. To determine whether the moisture 
present in the polymer produced a basic pH microenvironment which influenced 
degradation, pH of the pure Soluplus® slurry was measured and found to be 7.5. 
Soluplus® contains 2-5% (w/w) moisture which was suspected to cause the alkaline 
microenvironment which promoted artemisinin degradation. In an attempt to counteract 
this degradation, small amounts of citric acid were added to the drug and polymer 
mixture to reduce the pH and the number of heavy metal ions potentially responsible for 
the discolouration. In addition to prevention of degradation, pH modifier can increase 
the dissolution profile, reduce the crystallinity of API and inhibit the recrystallization of 
a solid dispersion system23. Yang et al reported that the selection of the acid was 
important for controling the pH of a system and the interactions in the final solid 
dispersion24. Rheological characterisations were carried out with the addition of 2 and 
5% (w/w) citric acid to the 50% artemisinin physical mixture. No discolouration of the 
samples containing 5% citric acid was observed but some discolouration was present 
with 2% (w/w) citric acid. This indicates that citric acid suppressed degradation by 
avoiding the exposure of artemisinin to an alkaline microenvironment. When the 
physical mixture (1:1), containing 5% citric acid, was processed at 110°C, there was a 
slight decrease in the complex viscosity for the initial 3 minutes, followed by the 
viscosity remaining relatively constant (as shown in Fig.2). It was therefore decided to 
investigate formulations with and without addition of citric acid in HME. 
Extrusion 
From the results of thermal and rheological characterisations, formulations were 
processed using HME at a set temperature of 110°C with a 50% artemisinin loading.  
Artemisinin and polymer were extruded, together with a separate batch containing 50% 
drug, 45% polymer and 5% citric acid.  An extruder temperature profile of 110°C was 
used, being found to generate moderate levels of torque on the extruder screws and to 
provide a suitable extrudate consistency.  Due to the thermally sensitive nature of the 
material, full and half-length screws were used to vary the residence time of the material 
at temperature. Three formulations were extruded for further analysis:  ArtSD1, ArtSD2 
and ArtSD3. ArtSD1 was produced using the half length extruder screw configuration 
whereas ArtSD2 (without citric acid) and ArtSD3 (with citric acid) were produced using 
a full length extruder screw configurations. Full details of temperature profiles, screw 
configurations and formulations are summarised in Tables 1, 2 and 3 respectively.  
Assay 
Artemisinin does not contain a chromophore and hence it was difficult to find a 
sensitive and appropriate analytical method. A UV method was selected which involved 
post derivatisation. This was based on the formation of an alkali salt of artemisinin 
(Q292) formed by treatment with 0.2% NaOH at 40°C, however the product was not 
coloured25. From visual observation of the extrudates, ArtSD2 was darker in colour 
compared to ArtSD1. This degradation was mirrored in the assays; 83.30% and 78.65% 
for ArtSD1 and ArtSD2 respectively. However, the modified formulation ArtSD3 
(containing citric acid) was found to be 99.76%.  As ArtSD3 yielded the highest drug 
content, this formulation was used for further characterisation. All assay results are 
presented in Table 4. 
Thermal analysis  
DSC thermograms of artemisinin, Soluplus® and their physical mixture are shown in 
Fig. 4. Artemisinin exhibited two melting endotherms a major endotherm at 154.81°C 
and an exotherm at 180°C, representing the liberation of formic acid, the same 
exotherm was also observed in the physical mixture but commenced at a lower 
temperature. Soluplus® exhibited a Tg at 70°C whereas the physical mixture exhibited 
Tg at 80°C and a sharp endotherm at 154.75°C.  
The DSC thermograms of citric acid, the physical mixture containing 5% citric acid and 
ArtSD3 are shown in Fig. 5. Citric acid exhibited a melting endotherm at 156°C 
followed by thermal degradation. The physical mixture containing citric acid exhibited 
a glass transition temperature at 90°C. ArtSD3 showed an exotherm at 180°C, 
representing the liberation of formic acid; however the material did not exhibit a 
melting endotherm corresponding to that of artemisinin, indicating that an amorphous 
state of the solid dispersion had been achieved.  
Powder X-ray Diffractometry 
The effect of processing parameters on physical properties was examined by comparing 
X-ray diffraction patterns of ArtSD3 with artemisinin, Soluplus® and physical mixtures 
as shown in Fig. 6. Artemisinin exhibited characteristic peaks at 2θ of 7.5, 12, 14.5, 
20.2 and 21.9 degrees, while Soluplus®, being amorphous in nature, did not show any 
crystalline peaks. For the physical mixture, crystalline peaks of artemisinin were clearly 
observed. The complete disappearance of crystalline peaks in ArtSD3 illustrated that the 
prepared solid dispersion using Soluplus® was transformed into an amorphous state. 
The intensity of the crystalline peaks was low for the physical mixture when compared 
to those for pure artemisinin. This signifies that the presence of Soluplus® had no 
influence on the physical state of artemisinin.  
In-vitro dissolution study 
The pharmaceutical performance of the extrudates was investigated by in-vitro 
dissolution and compared with the pure drug and physical mixture, as shown in Fig. 7. 
The dissolution profile of ArtSD3 was significantly higher compared to that of the pure 
drug. The dissolution rate of the physical mixture was greater than that of pure 
artemisinin, although not considerably. In the first 45 minutes, 92% of the drug was 
released from ArtSD3 which is presumably due to transferring the crystalline state to 
the amorphous state resulting in a higher dissolution rate. This compared to release of 
only 12% in the same time for pure Artemisinin. In a previous study, 75% of drug 
release was achieved in 60 minutes from solid dispersions of artemisinin with PVP (1:5 
ratio) prepared by supercritical fluid technology16. Therefore, Soluplus® was found to 
be more effective in improving the dissolution rate of artemisinin. Soluplus® has the 
ability to solubilise the hydrophobic drug due to its amphiphilic nature through micelle 
formation26. In addition, the incorporation of pH modifier may have contributed to 
dissolution enhancement.   
Artemisinin is a Biopharmaceutical Classification System (BCS) class II drug meaning 
that it has low solubility and high permeability. It has been reported that artemisinin has 
only 8-10% bioavailability, a short half-life and a high first pass metabolism27; these 
properties contribute to partial parasite removal resulting in artemisinin 
recrudescences16. Jinadasa et al observed that the absorption of artemisinin was 
negligible when it reached the lower gastrointestinal (GI) tract specifically the colon28. 
Thus, enhancing the solubility of artemisinin could ensure better drug dissolution in the 
upper GI tract, greater bioavailability and in turn lower chances of recrudescence. A 
rapid dissolution rate and hence absorption could lead to enzyme saturation during the 
first pass in the liver, resulting in a higher fraction of unmetabolized drug entering the 
systemic circulation, compared to a slower rate of drug dissolution.  
Pharmacokinetic study  
The bioavailability of pure artemisinin and ArtSD3 were studied in albino rats, in order 
to verify the correlation between in vivo data and data obtained by the in vitro 
dissolution method. Twelve rats were used for each formulation and samples were 
analysed once. A plasma concentration against time curve was obtained after oral 
administration of formulations. The plasma concentrations for pure artemisinin and 
ArtSD3 are displayed in Table 5 and 6 respectively. Plasma concentration of ArtSD3 
clearly shows the enhanced bioavailability of ArtSD3 compared to the pure drug, as 
shown in Fig. 8. Maximum artemisinin concentration in plasma was reached by ArtSD3 
which is approximately five times greater than the pure drug demonstrating significantly 
improved release in the amorphous state. A typical chromatogram of a rat plasma 
sample spiked with 120 µg/ml artemisinin RT 9.96 and internal standard artemether RT 
16.68 is shown in Fig. 9. The areas under the curves for both pure artemisinin and 
ArtSD3 are shown in table 7. ArtSD3 showed a three-fold increase in AUC compared to 
pure artemisinin. The average Cmax concentration (maximum plasma concentration) for 
artemisinin and the ArtSD3 were 16µg/ml and 40µg/ml respectively, whereas Tmax (time 
to reach Cmax) was 4 hours for both.  
Stability 
Although an interest in solid dispersions is growing rapidly, the commercialisation of 
solid dispersions in the pharmaceutical industry is limited. The formulation stability is a 
major issue for solid dispersions owing to phase separation29. There are also chances of 
crystallisation occurring during storage as the drug is molecularly dispersed. The PXRD 
pattern, DSC thermograms and dissolution profiles of the solid dispersion (ArtSD3) 
were analysed after 1, 3, 6, 9 and 12 months. The amorphous solid dispersion was found 
to be stable for more than a year without evidence of recrystallization. The improved 
stability of ArtSD3 during storage is attributed to strong intermolecular interaction 
between the drug and polymer which reduces the chances of molecular mobility and 
recrystallization.   
4. Conclusions 
A novel melt extruded formulation of the poorly soluble thermolabile drug artemisinin 
was developed, using the amphiphilic copolymer Soluplus®. The extruded material was 
completely amorphous in nature and a small amount of citric acid was incorporated to 
suppress degradation of the drug at extrusion temperatures. Release rates of the drug 
were significantly improved compared to the pure drug and physical mixture or drug 
and polymer, in both in vitro and in vivo studies. The system was shown to be stable up 
to at least 12 months, highlighting the potential for enhancement in delivery of this 
important but challenging API. 
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Tables  
Table 1. Temperature profiles across the different zones of the extruder barrel 
Temperature  
Profile  
Zone 2 3 4 5 6 7 8 9 Die 
T110 A - - - - 25 25 110 110 110 
T110 B 20 25 80 90 100 110 110 110 110 
 
Table 2. Screw configurations 
(a: in terms of diameter   ID: 16 mm) 
A  B  
Length 
(D)a 
Element  
 
 
 
Length 
(D)a 
Element  
 
 
 
9 Forwarding 28 Forwarding 
2.25 30° 2.25 30° 
1.25 60° 1.25 60° 
1 90° 1 90° 
6 Forwarding 6 Forwarding 
1.5 Discharge 1.5 Discharge 
20 Total length 40 Total Length 
 
Table 3. Formulations codes with process parameters   
 
 
  
 
 
 
 
Batches 
Screw 
configuration 
(shown in 
Table 3.3) 
Proportion Temperature 
Profiles 
(shown in 
Table 3.4) 
Visual  
Observation Drug Polymer Citric 
acid 
ArtSD1 A 
(Half screw 
length) 
1 1 - T110A 
 
ArtSD2 B 
(Full screw 
length) 
1 1 - T110B 
 
ArtSD3 B 
(Full screw 
length)  
1 0.95 0.05 T110 
 
 
 
Table 4. Assay results of extrudates 
 
Formulations Average Purity (%) Standard deviation 
ArtSD1 83.30 1.85 
ArtSD2 78.65 2.79 
ArtSD3 99.76 3.54 
Extruded artemisinin 
crystals (neat) 
99.33 0.57 
Extruded Soluplus® 
(neat) 
- - 
 
 
 
 
Table 5. Plasma concentration of pure artemisinin 
 
  Plasma Concentration of pure artemisinin(µg/ml) 
Time(h) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean 
0 0 0 0 0 0 0 0 
0.5 7.78 6.67 7.78 7.78 8.89 6.67 7.59 
1 15.56 8.89 10 11.11 12.22 17.78 12.59 
2 31.11 8.89 10 11.11 12.22 17.78 15.18 
4 18.89 17.78 20 18.89 17.78 16.67 18.33 
6 16.67 12.22 10 8.89 7.78 7.78 10.55 
8 10 7.78 7.78 6.67 6.67 6.67 7.59 
24 8.89 10 8.89 6.67 7.78 8.89 8.51 
 
Table 6. Plasma concentration of ArtSD3 
Plasma Concentration of ArtSD3 (µg/ml) 
Time(h) Rat 1 Rat 2 Rat 3 Rat 4 Rat 5 Rat 6 Mean 
0 0 0 0 0 0 0 0 
0.5 22.22 24.44 21.11 22.22 23.33 20.00 22.22 
1 27.78 26.67 26.67 26.67 28.89 27.78 27.41 
2 33.33 31.11 28.89 34.44 32.22 35.56 32.59 
4 43.33 41.11 45.56 41.11 42.22 42.22 42.59 
6 26.67 33.33 35.56 32.22 33.33 35.56 32.78 
8 20.00 23.33 28.89 27.78 30.00 31.11 26.85 
24 13.33 18.89 20.00 18.89 20.00 17.78 18.15 
Table 7. Area under curves for pure artemisinin and ArtSD3 
Rats Pure artemisinin 
(µg.hr/ml) 
ArtSD3  
(µg.hr/ml) 
Rat 1 47.01 127.15 
Rat 2 58.33 147.22 
Rat 3 37.77 164.03 
Rat 4 32.56 157.64 
Rat 5 34.65 165.49 
Rat 6 55.83 165.49 
  
